Neoadjuvant Immune Checkpoint Blockade in Upper Tract Urothelial Carcinoma – Expert Commentary

The definitive treatment for high-grade localized upper tract urothelial carcinoma (UTUC) is radical nephroureterectomy (RNU). Neoadjuvant pembrolizumab was tested in patients with muscle-invasive bladder cancer before radical cystectomy and demonstrated promising efficacy in the PURE-01 trial. However, it is unclear if patients with UTUC will draw a similar benefit.

Novartis Presents Important Overall Survival and Quality-of-Life Results Across Solid Tumor Portfolio at ESMO

New Kisqali® (ribociclib)* overall survival (OS) results from MONALEESA-2 trial in HR+/HER2− advanced breast cancer patients in the first-line setting Health-related quality of life, pain and safety outcomes from phase III VISION trial of investigational radioligand therapy 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer Data supporting upcoming regulatory filings for tislelizumab in people with squamous and […]

Clinical Efficacy of Multi-Focal Low-Intensity Extracorporeal Shockwave Therapy in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Prospective-Randomized, Double Blind, Placebo-Controlled Study.

To assess the safety and effect of the multifocal low-intensity extracorporeal shockwave therapy (MESWT) in the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). We randomly separated 30 patients with CP/CPPS into a MESWT and placebo group of same number using prospective-randomized, double-blind design.

A comprehensive narrative review of residual curvature correction during penile prosthesis implantation in patients with severe erectile dysfunction and concomitant Peyronie’s disease.

Residual curvature correction during penile prosthesis implantation (PPI) is usually needed in patients with severe erectile dysfunction (ED) and concomitant Peyronie’s disease (PD). The aim of the study was to assess the different existing techniques for treating residual penile curvature during PPI in patients with severe PD and ED.

X